Abstracts tagged "gout"

Abstract Number: 1909 • 2012 ACR/ARHP Annual Meeting
Use of Uric Lowering Therapies within a Large Health Care System
Robert A. Overman¹, Brian F. Mandell² and Chad L. Deal³, ¹Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ²Dept of Rheum/Immun NA10, The Cleveland Clinic, Cleveland, OH, ³Dept of Rheum & Imm Dis /A 50, Cleveland Clinic, Cleveland, OH
Background/Purpose: Guidelines for initiating urate lowering therapy (ULT) in the treatment of gout recommend treatment to a target serum urate (SUA) level of ≤6mg/dl with…
Abstract Number: 167 • 2012 ACR/ARHP Annual Meeting
Serum Uric Acid Control and Risk of Flare According to Different Cut-Offs in Patients with Gout: Longitudinal Analysis From the King Study of the Italian Society for Rheumatology
Maria Manara¹, Carlo Alberto Scirè¹, Marco A. Cimmino², Marcello Govoni³, Fausto Salaffi⁴, Greta Carrara¹, Carlomaurizio Montecucco⁵, Marco Matucci-Cerinic⁶, Giovanni Minisola⁷ and Kick-off of the Italina Network for Gout (KING) Study Group⁸, ¹Epidemiology Unit -Italian Society for Rheumatology, Milano, Italy, ²Rheumatology - Department of Internal Medicine - University of Genoa, Genova, Italy, ³Clinical and Experimental Medicine, Section of Rheumatology, University of Ferrara, Ferrara, Italy, ⁴Rheumatology Unit - Polytechnic University of the Marche, Jesi, Italy, ⁵Division of Rheumatology - University of Pavia School of Medicine, IRCCS Policlinico San Matteo Foundation, Pavia, Italy, ⁶Department of Biomedicine & Division of Rheumatology AOUC - University of Florence, Florence, Italy, ⁷Rheumatology Unit - San Camillo Forlanini Hospital, Rome, Italy, ⁸Italian Society for Rheumatology, SIR, Italy
Background/Purpose: the therapeutic goal of the management of gout is to promote crystal dissolution and prevent crystal formation. For this reason national and international guidelines…
Abstract Number: 1911 • 2012 ACR/ARHP Annual Meeting
Efficacy and Safety of Canakinumab Vs Triamcinolone Acetonide in Patients with Gouty Arthritis Unable to Use Nonsteroidal Anti-Inflammatory Drugs and Colchicine, and On Stable Urate Lowering Therapy (ULT) or Unable to Use ULT
T. Bardin¹, A. So², R. Alten³, M. Bloch⁴, M. R. John⁵, G. Krammer⁵, J. M. Nebesky⁵, A. Tao⁶ and N. Schlesinger⁷, ¹Service de Rhumatologie, Hôpital Lariboisière, Paris, France, ²Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland, ³Charité Univ Medicine, Berlin, Germany, ⁴Holdsworth House Medical Practice, Sydney, Australia, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁷UMDNJ-Robert Wood Johnson Medical School, New Brunswick, NJ
Background/Purpose: The primary treatment goals for gouty arthritis (GA) are rapid relief of pain and inflammation during acute attacks, and long-term hyperuricemia management. A post-hoc…
Abstract Number: 168 • 2012 ACR/ARHP Annual Meeting
Allopurinol Use Is Associated with a Decreased Risk of Myocardial Infarction
Lamiae Grimaldi-Bensouda¹, Annick Alpérovitch², Elodie Aubrun¹, Nicolas Danchin³, Michel Rossignol⁴, Lucien Abenhaim⁵, Pascal Richette⁶ and PGRx MI Group⁷, ¹LA-SER, Paris, France, ²Inserm U708-Neuroepidemiology, La Pitié-Salpêtrière Hospital, Paris, France, ³Coronary disease unit, Georges Pompidou European Hospital, Assistance Publique-Hôpitaux de Paris and Paris-Descartes University, Paris, France, ⁴LA-SER, Centre for Risk Research, Montreal, Canada, ⁵LA-SER Europe Ltd, London, United Kingdom, ⁶Lariboisière Hospital, Paris, France, ⁷Paris, France
Background/Purpose: Xanthine oxidase inhibitors (XOI) reduce both urate levels and the oxidative stress in the vasculature, which are known cardiovascular risk factors. However, the effects…
Abstract Number: 1912 • 2012 ACR/ARHP Annual Meeting
Colchicine, As Assessed by Target Joint Pain Scores, Is Effective At 16 Hours in Patients with Acute Gout Flares
Suman Wason¹, Thomas Lauterio¹, Steve Crockett¹ and Matthew W. Davis², ¹Clinical Development, URL Pharma, Philadelphia, PA, ²Clinical Pharmacology, URL Pharma, Philadelphia, PA
Background/Purpose: The management of patients with gout remains suboptimal, leading to increasing frequency and severity of recurrent flares that eventually lead to joint destruction and…
Abstract Number: 150 • 2012 ACR/ARHP Annual Meeting
Ulodesine (BCX4208) Long-Term Safety When Added to Allopurinol in the Chronic Management of Gout: A Phase 2 24-Week Blinded Safety Extension and Vaccine Challenge Study
Alan S. Hollister¹, Andreas Maetzel¹, Michael A. Becker², Robert Terkeltaub³, David Fitz-Patrick⁴, Valerie Smith⁵ and William P. Sheridan⁶, ¹Development, BioCryst Pharmaceuticals, Inc., Durham, NC, ²Medicine, University of Chicago, Chicago, IL, ³Medicine-Rheumatology, VA Medical Ctr/University of California San Diego, San Diego, CA, ⁴East-West Medical Research Institute, Honolulu, HI, ⁵Pharpoint Research, Inc., Durham, NC, ⁶BioCryst Pharmaceuticals, Inc., Durham, NC
Background/Purpose: A majority of gout patients treated with 300 mg/d allopurinol do not reach the therapeutic goal range serum uric acid concentration (sUA) of 4…
Abstract Number: 1914 • 2012 ACR/ARHP Annual Meeting
The Diagnosis and Management of Gout in 2012: Survey of US and Canadian Rheumatologists
John J. Cush¹ and Robert T. Keenan², ¹Baylor Research Institute, Dallas, TX, ²Rheumatology, Duke University, Durham, NC
Background/Purpose: The introduction of novel treatment modalities for gout has escalated interest and education on this topic. Although gout is the most common inflammatory arthropathy…
Abstract Number: 152 • 2012 ACR/ARHP Annual Meeting
Rilonacept for Gout Flare Reduction: Estimation of Number Needed to Treat to Benefit (NNTB)
Robert R. Evans¹, Steven P. Weinstein², George D. Yancopoulos³ and Yuhwen Soo⁴, ¹Clinical Sciences, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ²Clinical Development, Regeneron Pharmaceuticals Inc, Tarrytown, NY, ³Research Labs, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, ⁴BioStatistics, Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Two similarly designed phase 3 randomized clinical trials (PRESURGE-1 and PRESURGE-2) in gout patients initiating urate-lowering therapy (ULT) showed that subcutaneous treatment with the…
Abstract Number: 1915 • 2012 ACR/ARHP Annual Meeting
Elevated Serum Homocysteine Levels Were Related Not with Serum Uric Acid Levels but with Decreased Renal Function in Chronic Gouty Patients
Sang Tae Choi¹, Jung-Soo Song¹, Jin Su Kim², Eun-Jin Kang³, Kwang-Hoon Lee⁴ and You-Jung Ha⁵, ¹Rheumatology, Chung-Ang University College of Medicine, Seoul, South Korea, ²Chung-Ang University College of Medicine, Seoul, South Korea, ³Rheumatology, Busan Medical Center, Busan, South Korea, ⁴Dongguk University Ilsan Hospital, Goyang, South Korea, ⁵Kwandong University college of Medicine, Goyang, South Korea
Background/Purpose: Hyperhomocysteinemia, which is related with cardiovascular diseases and metabolic syndrome, is regarded as one of the important factors in endothelial cell damage processes. It…
Abstract Number: 156 • 2012 ACR/ARHP Annual Meeting
Menopause and the Prevalence of Gout and Hyperuricemia: An Age-Matched Case Control Study
Eswar Krishnan¹ and Mihoko Bennett², ¹Medicine, Standford University, Palo Alto, CA, ²Pediatrics, Stanford University, Palo Alto, CA
Background/Purpose: Among women, the prevalence of gouty arthritis (gout) and hyperuricemia (serum urate>6.0 mg/dL) increases steeply after the age 60. This increase has been attributed…
Abstract Number: 1813 • 2012 ACR/ARHP Annual Meeting
Accuracy of Veterans Affairs Database for Gout-Related Health Care Utilization
Jasvinder A. Singh, Department of Medicine, University of Alabama, Tuscaloosa, AL
Background/Purpose: Gout outcome studies have used administrative and claims databases. It is unknown whether administrative-derived data are accurate for gout-related utilization. The goal of the…
Abstract Number: 157 • 2012 ACR/ARHP Annual Meeting
Prevalence of Gout Among Adults with Chronic Kidney Disease in the United States, 2009-10
Eswar Krishnan, Medicine, Standford University, Palo Alto, CA
Background/Purpose: The kidney is a major route of clearance of uric acid, a product of purine metabolism. The links between kidney disease, hyperuricemia, and gout…
Abstract Number: 1814 • 2012 ACR/ARHP Annual Meeting
Comparing Clinical Characteristics and Comorbidities of Gout Patients Treated with Allopurinol or Febuxostat
Michael A. Becker¹, Xiangyang Ye², Kasem S. Akhras³, Rima H. Tawk⁴, Sudhir Unni², Jason Young² and Carl V. Asche⁵, ¹Medicine, University of Chicago, Chicago, IL, ²University of Utah College of Pharmacy, Salt Lake City, UT, ³Global Outcomes Research, Takeda Pharmaceuticals International, Inc., Deerfield, IL, ⁴Center for pharmacoeconomic Research, University of Illinois at Chicago, Chicago, IL, ⁵Center for Outcomes Research, University of Illinois College of Medicine at Peoria, Peoria, IL
Background/Purpose: Gout is a common acute and potentially progressive disease affecting approximately 8 million Americans. Hyperuricemia (serum urate levels [sUA] >6.8mg/dL) is a major pathogenic…
Abstract Number: 158 • 2012 ACR/ARHP Annual Meeting
Focus Groups Reveal Knowledge Gaps in Patients with Gout-A Qualitative Study
Puja Khanna¹, Veronica Berrocal², Tonya Hays³, Daniel J. Clauw⁴ and David A. Williams⁵, ¹Division of Rheumatology/Dept. of Internal Medicine, University of Michigan, Ann Arbor, MI, ²Department of Biostatistics- School of Public Health, University of Michigan, Ann Arbor, MI, ³Survey Research Center, UCLA, Los Angeles, CA, ⁴Anesthesiology/Internal Medicine (Rheum), University of Michigan, Ann Arbor, MI, ⁵Chronic Pain & Fatigue Rsch Ctr, Univ of MI Hlth System-Lobby M, Ann Arbor, MI
Background/Purpose: Gout is the most treatable arthritis in the Western World and there are effective medications available to treat both acute episodes and chronic gout.…
Abstract Number: 1816 • 2012 ACR/ARHP Annual Meeting
Relationship Between Race, Uric Acid Levels, Urate-Lowering Therapy and Resource Use in Patients with Gout
Kim Coley¹, Melissa Saul² and Karen Pater¹, ¹Pharmacy & Therapeutics, University of Pittsburgh, Pittsburgh, PA, ²Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Gout is a chronic inflammatory disease caused by the deposition of monosodium urate crystals in joints and soft tissues. The overall prevalence is increasing…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.